Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02145143
Title Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Recruitment Active, not recruiting
Gender both
Phase Phase 0
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

thyroid gland follicular carcinoma

thyroid gland papillary carcinoma

Therapies

Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST